Welcome to the e-CCO Library!

P726: Trough levels of infliximab better correlate with combined mucosal and transmural healing than clinical remission in Korean patients with Crohn’s disease on infliximab maintenance therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. H. Oh*1, A-R. Yoon2, S. H. Park3, J. Kim1, N. Ham1, E. M. Song1, S. W. Hwang1,2, S. H. Park1,2, D-H. Yang1, J-S. Byeon1, S-J. Myung1, S-K. Yang1,2, B. D. Ye1,2

Created: Friday, 22 February 2019, 9:41 AM
P727 Small bowel capsule endoscopy impact on therapeutic decisions in established Crohn’s disease: Analysis of a real-world data
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E.J. Gómez, R.A. Gonzalez, L. Pereyra, J.M. Mella, G.N. Panigadi, C. Fischer, M. Roel, D.G. Cimmino, S. Pedreira, L.A. Boerr

Created: Thursday, 30 January 2020, 10:12 AM
P727: Change in Crohn's disease behavior in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Burisch J.*1, Halfvarson J.2, Kupcinskas L.3, Hernandez V.4, Kaimakliotis I.5, Valpiani D.6, Pedersen N.7, Duricova D.8, Kievit L.9, Dahlerup J.F.10, Fumery M.11, Salupere R.12, Arebi N.13, Nielsen K.R.14, Giannotta M.15, Oksanen P.16, Katsanos K.H.17, Vegh Z.18, Ellul P.19, Schwartz D.20, Čuković-Čavka S.21, D'Incà R.22, Turcan S.23, Magro F.24,25,26, Goldis A.27, Langholz E.28, Lakatos P.L.18, Munkholm P.1 EpiCom Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P727: Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Macaluso, F.S.(1)*;Ventimiglia, M.(2);Orlando, A.(3);
Created: Friday, 14 July 2023, 11:12 AM
P727: Efficacy of vedolizumab (VDZ) by disease localisation in Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Allez1*, F. Braegger2, C. Kempf2, P. Michetti3

Created: Thursday, 21 February 2019, 9:14 AM
P727: Quality of life and disease activity in children and adolescents with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Aloi*1, E. Carloni1, F. Palmacci1, M. Distante1, G. Catassi1, G. D'Arcangelo1, S. Cucchiara1, AMICI Italian IBD Association1

Created: Friday, 22 February 2019, 9:41 AM
P728 Comparative assessment of faecal microbiota transplantation and current therapies as induction treatment for active refractory ulcerative colitis: A systematic review and network meta-analysis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Malandris1, P. Paschos1, A. Koukoufiki1, A. Katsoula1, A. Manolopoulos1, A. Tsapas1,2, E. Bekiari1

Created: Thursday, 30 January 2020, 10:12 AM
P728: Changes in the use of biologics in the treatment of IBD patients over time. Results from a comprehensive Norwegian registry study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Svatun Lirhus S.*1, Melberg H.O.1,2, Lie Høivik M.3, Moum B.3

Created: Wednesday, 20 February 2019, 10:36 AM
P728: Effectiveness and quality of life (QoL) of Ustekinumab (UST) therapy in a Real-world Setting in Germany – First Results of the RUN-CD Study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Bokemeyer*1,2, S. Plachta-Danielzik3, N. Teich4, W. Mohl5, M. Hoffstadt6, A. Schweitzer7, M. von der Ohe8, T. Krause9, J. Höchstödter3, P. Hartmann1, B. Wiebe3, S. Schreiber2

Created: Friday, 22 February 2019, 9:41 AM
P728: Efficacy of anti-TNF treatment in patients with refractory ulcerative proctitis: Results from a French retrospective multi-centre national cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Pineton de Chambrun1*, A. Amiot2, G. Bouguen3, S. Viennot4, R. Altwegg1, E. Louis5, M. Collins6, M. Fumery7, F. Poullenot8, L. Armengol9, A. Buisson10, V. Abitbol11, Y. Bouhnik12, D. Laharie8, P. Seksik13, S. Nancey14, P. Blanc1, M. Nachury15, L. Peyrin-Biroulet16

Created: Thursday, 21 February 2019, 9:14 AM
P728: Real world evidence for adalimumab biosimilar, MSB 11022, therapy in inflammatory bowel diseases: Adherence analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cheung, S.(1)*;Truong, D.(1);
Created: Friday, 14 July 2023, 11:12 AM
P729 The SAPPHIRE registry: Safety of immunosuppression in a prospective cohort of inflammatory bowel disease patients with a HIstoRy of CancEr
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Axelrad1, J.F. Colombel2, E. Scherl3, D. Lukin3, S. Chang1, L. Chen1, J. Kwah4, A. Swaminath5, K. Sultan5, G. Lawlor6, C. Villagra2, J. Galanko7, V. Sharpless7, S. Itzkowitz2, New York Crohn’s and Colitis Organization (NYCCO)

Created: Thursday, 30 January 2020, 10:12 AM
P729: A ‘real-world’ retrospective multi-centre study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Kronsten1*, M. Colwill1, S. Nayeemuddin2, J. Limdi2,3, C. Selinger4, G. Scott5, L. Al-Hillawi6, S. Salehi6, P. Blaker6, G. Chung-Faye1, A. Kent1, P. Dubois1, B. Hayee1

Created: Thursday, 21 February 2019, 9:14 AM
P729: Evaluation of hepatobiliary pathologies using transient elastography in patients with inflammatory bowel disease: What about the effect of drugs?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ağargün, B.F.(1);Şenkal, İ.V.(2);Rustamzade, A.(2);Nuriyev, K.(2);İstemihan, Z.(2);İmanov, Z.(2);Genç, S.(2);Çelik, B.(3);Şahutoğulları, D.(3);Çavuş, B.(2);Çifcibaşı Örmeci, A.(2);Demir, K.(2);Beşışık, S.F.(2);Kaymakoğlu, S.(2);Akyüz, F.(2)*;
Created: Friday, 14 July 2023, 11:12 AM
P729: Faecal calprotectin and faecal immunochemical test have different values depending on mucosal status in patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. W. Kim*1, S. B. Park1, C. W. Choi1, D. H. Kang1, D. G. Ryu1

Created: Friday, 22 February 2019, 9:41 AM
P729: Increased requirement for steroids, thiopurines and intestinal surgery in Crohn's patients who are smokers at IBD diagnosis; a nationwide population based study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Alexakis C.*1, Saxena S.2, Chhaya V.1, Cecil E.2, Pollok R.1

Created: Wednesday, 20 February 2019, 10:36 AM
P730 Effectiveness and safety of endoscopic balloon dilation of colorectal strictures in Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. TILMANT1, M. serrero2, F. Poullenot3, G. Bouguen4, B. Pariente5, R. Altwegg6, P. Basile7, J. Filippi8, P. Vanelslander9, A. Buisson10, L. Vuitton11, A. Desjeux2, D. Laharie3, E. Le Balch4, M. Nachury5, L. Boivineau6, G. Savoye7, X. Hebuterne8, L. Poincloux10, A. Lamrani12, M. Fumery1

Created: Thursday, 30 January 2020, 10:12 AM
P730: Anti tumor necrosis factor treatment in Ulcerative Colitis: Real-world data and evaluation of current treatment targets (STRIDE II)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lundekvam, J.A.(1,2)*;Lie Høivik, M.(1,2);Anisdahl, K.(1,2);Cvancarova Småstuen, M.(3);Medhus, A.W.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P730: Disease phenotype of Korean paediatric Crohn's disease patients at diagnosis: a multicentre retrospective comparative study with EUROKIDS
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kang B.*1, Kim J.-E.2, Kim S.3, Kim M.J.4, Lee Y.M.5, Lee J.H.6, Lee J.-H.7, Lee H.J.8, Lee Y.9, Choe Y.H.1, Choe B.-H.2

Created: Wednesday, 20 February 2019, 10:36 AM
P730: High-dosed intravenous iron replacement therapy does not hinder drug-induced amelioration of disease activity in IBD patients with iron deficiency anaemia
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Stein1,2*, S. Vollmer3, W. Klemm4, K. Nip5, S. Weber-Mangal5, A. Dignass1,6

Created: Thursday, 21 February 2019, 9:14 AM